Tarsus Pharmaceuticals, Inc. GAAP EPS of -$0.30 beats by $0.04, revenue of $118.7M beats by $3.48M

2 hours ago 1

Tarsus Pharmaceuticals, Inc. press release (TARS): Q3 GAAP EPS of -$0.30 beats by $0.04.
Revenue of $118.7M (+146.8% Y/Y) beats by $3.48M.
- XDEMVY is continuing on a strong growth trajectory with Q3 results of:
  - $118.7 million in net product sales.